| CAS ID: | 6217-54-5 |
| Molecular Formula: | C22H32O2 |
| Molecular Weight: | 328.5 g/mol |
| Monoisotopic Mass: | 328.2402 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | DOCONEXENT | OMEGA-3 MARINE TRIGLYCERIDES |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18- | See All |
| InChI Key: | MBMBGCFOFBJSGT-KUBAVDMBSA-N | |
| Smiles: | CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 28393852 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,mice | Fibrosis Disease | Renal fibrosis |
| Process I | |||
| Process II | fibroblasts activation | ||
| Process III | |||
| Mechanism | Targeting mTORC2 signaling | ||
Trial Record 1
| ClinicalTrial ID | NCT00924547 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | June 19, 2009 | Last Verified | July 21, 2015 |
| Sponsor | Vanderbilt University | ||
Trial Record 2
| ClinicalTrial ID | NCT00530244 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | September 17, 2007 | Last Verified | March 7, 2018 |
| Sponsor | University of Massachusetts, Worcester | ||
Trial Record 3
| ClinicalTrial ID | NCT02690857 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | February 24, 2016 | Last Verified | February 24, 2016 |
| Sponsor | Hospices Civils de Lyon | ||
Trial Record 4
| ClinicalTrial ID | NCT02518672 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Terminated |
| First Received | August 10, 2015 | Last Verified | October 4, 2017 |
| Sponsor | SCF Pharma | ||
Trial Record 5
| ClinicalTrial ID | NCT00221546 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | September 22, 2005 | Last Verified | September 28, 2011 |
| Sponsor | University Hospital, Ghent | ||
Trial Record 6
| ClinicalTrial ID | NCT01783613 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | February 5, 2013 | Last Verified | April 26, 2017 |
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | ||
Trial Record 7
| ClinicalTrial ID | NCT01934777 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | September 4, 2013 | Last Verified | January 14, 2016 |
| Sponsor | Bambino Gesù Hospital and Research Institute | ||
Trial Record 8
| ClinicalTrial ID | NCT00885313 | Disease | Liver fibrosis |
| Phase | Phase 1,Phase 2 | Status | Completed |
| First Received | April 21, 2009 | Last Verified | May 13, 2011 |
| Sponsor | Bambino Gesù Hospital and Research Institute | ||
Trial Record 9
| ClinicalTrial ID | NCT03289806 | Disease | Bleb fibrosis |
| Phase | Status | Recruiting | |
| First Received | September 21, 2017 | Last Verified | September 21, 2017 |
| Sponsor | Centre Hospitalier Universitaire Dijon | ||
| PubChem: | 445580 |
| ChEMBL: | CHEMBL367149 |